RLRainer Lindner

Rainer Lindner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rainer Lindner has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Stefan Bartzsch

    Department of Radiation Oncology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany

    3 shared publications
  • Stephanie Elisabeth Combs

    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany

    3 shared publications
  • Thomas Ernst Schmid

    TUM School of Medicine and Health, Department of Radiation Oncology, TUM University hospital, Technical University of Munich, Munich, Germany

    3 shared publications
  • Aleksandra Čolić

    Department of Radiation Oncology, TUM School of Medicine and Health and Klinikum rechts der Isar, University Hospital of the Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany

    2 shared publications
  • Johanna Winter

    Department of Radiation Oncology, TUM School of Medicine and Health, Technical University Munich, 81675 Munich, Germany

    2 shared publications
  • Mabroor Ahmed

    Department of Radiation Oncology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany

    2 shared publications

Latest Publications

  • Open Access

    Targeting Lung Cancer Cell Motility Using Microbeam Radiation Therapy

    by Ömer Dağkazanlı, Aleksandra Čolić, Rainer Lindner, Stefan Bartzsch, Stephanie E. Combs, Thomas E. Schmid, Marina Santiago Franco

    Radiotherapy (RT) is currently among the standard treatments for lung cancer. However, in vitro studies have revealed that irradiation can increase lung cancer cell motility. This way, RT could potentially enhance the malignancy of solid tumors post-treatment, promoting metastasis. Therefore, there is a continued need to continue evolving RT modalities into safer and more effective treatments. The present study compares the impact of the broad beam (BB) and the spatially fractionated modality of microbeam radiation therapy (MRT) on the motility of A549 lung cancer cells. Our data corroborates previous findings that showed BB irradiation is a promoter of cell motility. For MRT, however, we observed a prevention of cellular migration. A significant reduction in NF-κB expression was observed only when A549 cells were irradiated with MRT, indicating a potential mechanism behind these findings. Finally, our data supports potential issues regarding MRT irradiation of key components of the tumor microenvironment, such as fibroblasts. Co-culturing A549 cells with MRT-irradiated MRC-5 lung fibroblasts led to increased tumor cell invasion, not observed when the fibroblasts received BB irradiation.


  • Open Access

    Superior Anti-Tumor Response After Microbeam and Minibeam Radiation Therapy in a Lung Cancer Mouse Model

    by Narayani Subramanian, Aleksandra Čolić, Marina Santiago Franco, Jessica Stolz, Mabroor Ahmed, Sandra Bicher, Johanna Winter, Rainer Lindner, Susanne Raulefs, Stephanie E. Combs, et al.

    Objectives: The present study aimed to compare the tumor growth delay between conventional radiotherapy (CRT) and the spatially fractionated modalities of microbeam radiation therapy (MRT) and minibeam radiation therapy (MBRT). In addition, we also determined the influence of beam width and the peak-to-valley dose ratio (PVDR) on tumor regrowth. Methods: A549, a human non-small-cell lung cancer cell line, was implanted subcutaneously into the hind leg of female CD1-Foxn1nu mice. The animals were irradiated with sham, CRT, MRT, or MBRT. The spatially fractionated fields were created using two specially designed multislit collimators with a beam width of 50 μm and a center-to-center distance (CTC) of 400 μm for MRT and a beam width of 500 μm and 2000 μm CTC for MBRT. Additionally, the concept of the equivalent uniform dose (EUD) was chosen in our study. A dose of 20 Gy was applied to all groups with a PVDR of 20 for MBRT and MRT. Tumor growth was recorded until the tumors reached at least a volume that was at least three-fold of their initial value, and the growth delay was calculated. Results: We saw a significant reduction in tumor regrowth following all radiation modalities. A growth delay of 11.1 ± 8 days was observed for CRT compared to the sham, whereas MBRT showed a delay of 20.2 ± 7.3 days. The most pronounced delay was observed in mice irradiated with MRT PVDR 20, with 34.9 ± 26.3 days of delay. Conclusions: The current study highlights the fact that MRT and MBRT modalities show a significant tumor growth delay in comparison to CRT at equivalent uniform doses.


  • Open Access

    In Vivo Microbeam Radiation Therapy at a Conventional Small Animal Irradiator

    by Mabroor Ahmed, Sandra Bicher, Stephanie Elisabeth Combs, Rainer Lindner, Susanne Raulefs, Thomas E. Schmid, Suzana Spasova, Jessica Stolz, Jan Jakob Wilkens, Johanna Winter, et al.

    Microbeam radiation therapy (MRT) is a still pre-clinical form of spatially fractionated radiotherapy, which uses an array of micrometer-wide, planar beams of X-ray radiation. The dose modulation in MRT has proven effective in the treatment of tumors while being well tolerated by normal tissue. Research on understanding the underlying biological mechanisms mostly requires large third-generation synchrotrons. In this study, we aimed to develop a preclinical treatment environment that would allow MRT independent of synchrotrons. We built a compact microbeam setup for pre-clinical experiments within a small animal irradiator and present in vivo MRT application, including treatment planning, dosimetry, and animal positioning. The brain of an immobilized mouse was treated with MRT, excised, and immunohistochemically stained against γH2AX for DNA double-strand breaks. We developed a comprehensive treatment planning system by adjusting an existing dose calculation algorithm to our setup and attaching it to the open-source software 3D-Slicer. Predicted doses in treatment planning agreed within 10% with film dosimetry readings. We demonstrated the feasibility of MRT exposures in vivo at a compact source and showed that the microbeam pattern is observable in histological sections of a mouse brain. The platform developed in this study will be used for pre-clinical research of MRT.